TheraRadar
Data updated: May 26, 2026

BROMSITE (bromfenac sodium)

Ophthalmology Approved 2016-04-08

Bromsite is an ophthalmic nonsteroidal anti-inflammatory drug (NSAID) used to manage recovery in patients who have undergone cataract surgery. It helps patients by reducing ocular pain and controlling inflammation that can occur after the procedure. This medication is typically prescribed to ensure a more comfortable healing process following lens replacement.

Source: FDA Label • Sun Pharma

How BROMSITE Works

This medication works by inhibiting the cyclooxygenase (COX) 1 and 2 enzymes, which effectively blocks the production of prostaglandins. By stopping these mediators of inflammation, the drug prevents issues like vasodilation, increased vascular permeability, and elevated intraocular pressure. This targeted action helps stabilize the blood-aqueous humor barrier and reduces the inflammatory response in the eye.

1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2016-04-08
Patent Cliff
2029

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: BROMFENAC SODIUM

BROMSITE Approval History

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2016 to 2023
Mar 2023 SUPPL
Label · Labeling
Apr 2016 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What BROMSITE Treats

2 indications

BROMSITE is approved for 2 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Inflammation
  • Ocular Pain
Source: FDA Label

BROMSITE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 10 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to BROMSITE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

BROMFENAC SODIUM
BROMFENAC SODIUM
2 shared
Apotex
Shared indications:
InflammationOcular Pain
PROLENSA
BROMFENAC SODIUM
2 shared
BAUSCH AND LOMB
Shared indications:
InflammationOcular Pain
ACULAR
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

BROMSITE FDA Label Details

Indications & Usage

FDA Label (PDF)

BROMSITE is indicated for the treatment of Inflammation; Ocular Pain.

View full patent landscape →
1 OB patents · 1 families · 13 international docs across 7 countries

BROMSITE Patents & Exclusivity

Latest Patent: Mar 2029

Patents (1 active)

USRE50218 Expires Mar 5, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for BROMSITE

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2029
  • 1 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.